search
Back to results

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study (Renal-HEIR)

Primary Purpose

Type 2 Diabetes Mellitus, Obesity, Nephropathy

Status
Active
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Aminohippurate Sodium Inj 20%
Iohexol Inj 300 MG/ML
Renal Biopsy
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Type 2 Diabetes Mellitus

Eligibility Criteria

12 Years - 21 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Obese youth with and without T2D (≥54 kg) and lean controls
  • Age 12-21 years
  • Weight <300 lbs., no implanted metal devices
  • HbA1c < 11% and no recent diabetic ketoacidosis or hyperosmolar hyperglycemia
  • No anemia
  • BMI >5th percentile for lean controls

Exclusion Criteria:

  • T2D onset (diagnosis) > 18 years of age
  • Prepubertal
  • eGFR <60ml/min/1.73m2 or creatinine > 1.5mg/dl or history of ACR≥300mg/g
  • ACE inhibitors, angiotensin receptor blockers (ARB), diuretics, sodium-glucose co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or aspirin, sulfonamides, procaine, thiazosulfone or probenecid.
  • Seafood or iodine allergy
  • Pregnancy
  • MRI scanning contraindications (claustrophobia, implantable devices, >300 lbs)

Additional exclusion criteria for participants undergoing optional kidney biopsy:

  • Evidence of bleeding disorder or complications from bleeding
  • Use of aspirin, NSAIDS or other blood thinner that cannot be safely stopped for a sufficient time period before and after the biopsy so as to add no additional risk of bleeding
  • Blood urea nitrogen (BUN) > 80 gm/dL
  • INR > 1.4
  • PTT > 35 seconds
  • Hemoglobin (Hgb) < 10 mg/dL
  • Platelet count < 100,000 / µL
  • Uncontrolled or difficult to control hypertension (> 150/90 mmHg at the day of biopsy)
  • eGFR < 40 mL/min/1.73m2
  • Single kidney (either by history, documented by prior imaging or ultrasound performed prior to the biopsy)
  • > 2 cm discrepancy between left and right kidney sizes based on largest longitudinal diameter determined by ultrasound performed prior to the biopsy.
  • Kidney size: One or both kidneys < 9 cm
  • Hydronephrosis or other important renal ultrasound findings such as significant stone disease
  • Any evidence of a current urinary tract infection as indicated on day of biopsy
  • Clinical evidence of non-diabetic renal disease
  • Positive urine pregnancy test or pregnancy

Sites / Locations

  • Children's Hospital Colorado

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Clinical Investigation

Arm Description

All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.

Outcomes

Primary Outcome Measures

Effective renal plasma flow (ERPF)
Measured by PAH clearance
Glomerular filtration rate (GFR)
Measured by iohexol clearance

Secondary Outcome Measures

Insulin sensitivity
Measured by hyperinsulinemic-euglycemic clamp
Renal oxygenation
Blood oxygen level dependent (BOLD) MRI
Renal perfusion
Arterial spin labeling (ASL) MRI

Full Information

First Posted
June 28, 2018
Last Updated
August 14, 2023
Sponsor
University of Colorado, Denver
search

1. Study Identification

Unique Protocol Identification Number
NCT03584217
Brief Title
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
Acronym
Renal-HEIR
Official Title
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 1, 2018 (Actual)
Primary Completion Date
June 30, 2023 (Actual)
Study Completion Date
October 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Type 2 diabetes (T2D) in youth is increasing in prevalence in parallel with the obesity epidemic. In the US, almost half of patients with renal failure have DKD, and ≥80% have T2D. Compared to adult-onset T2D, youth with T2D have a more aggressive phenotype with greater insulin resistance (IR), more rapid β-cell decline and higher prevalence of diabetic kidney disease (DKD), arguing for separate and dedicated studies in youth-onset T2D. Hyperfiltration is common in youth with T2D, and predicts progressive DKD. Hyperfiltration may also be associated with early changes in intrarenal hemodynamic function, including increased renal plasma flow (RPF) and glomerular pressure. Despite the high prevalence and gravity of DKD in youth-onset T2D, widely effective therapeutic options are lacking. The investigators' preliminary data support a strong association between IR and hyperfiltration in youth-onset T2D, but the pathology contributing to this relationship remains unclear. A better understanding of the pathophysiology underlying hyperfiltration and its relationship with IR is critical to inform development of new therapeutics. The investigators' overarching hypotheses are that: 1) hyperfiltration in youth-onset T2D is associated with changes in intrarenal hemodynamics, resulting in increased renal oxygen demand, 2) the demand is unmet by the inefficient fuel profile associated with IR (decreased glucose oxidation and increase free fatty acid [FFA] oxidation), resulting in renal hypoxia and ultimately renal damage. To address these hypotheses, the investigators will measure peripheral insulin sensitivity, adipose insulin sensitivity (FFA suppression), glomerular filtration rate (GFR), RPF, and renal oxygenation in youth with T2D (n=60), obesity (n=20) and in lean (n=20) controls. To further investigate the mechanisms of renal damage in youth with T2D, two optional procedures are included in the study: 1) kidney biopsy procedure and 2) induction of induced pluripotent stem cells (iPSCs) to assess morphometrics and genetic expression of renal tissue.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Obesity, Nephropathy, Adolescent Obesity

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Clinical Investigation
Arm Type
Other
Arm Description
All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
Intervention Type
Drug
Intervention Name(s)
Aminohippurate Sodium Inj 20%
Other Intervention Name(s)
Sodium 4-amino hippurate (PAH) inj 20% 2g/10mL, Para-aminohippurate, Aminohippuric acid
Intervention Description
Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Intervention Type
Drug
Intervention Name(s)
Iohexol Inj 300 MG/ML
Other Intervention Name(s)
omnipaque 300
Intervention Description
Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Intervention Type
Procedure
Intervention Name(s)
Renal Biopsy
Other Intervention Name(s)
Kidney Biopsy
Intervention Description
Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
Primary Outcome Measure Information:
Title
Effective renal plasma flow (ERPF)
Description
Measured by PAH clearance
Time Frame
4 hours
Title
Glomerular filtration rate (GFR)
Description
Measured by iohexol clearance
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Insulin sensitivity
Description
Measured by hyperinsulinemic-euglycemic clamp
Time Frame
4 hours
Title
Renal oxygenation
Description
Blood oxygen level dependent (BOLD) MRI
Time Frame
60 min
Title
Renal perfusion
Description
Arterial spin labeling (ASL) MRI
Time Frame
10 min
Other Pre-specified Outcome Measures:
Title
Podocyte numerical density and number per glomerulus
Description
Measured by light microscopy from tissue obtained by renal biopsy
Time Frame
4 hours
Title
Foot process width of glomeruli
Description
Measured by electron microscopy from tissue obtained by renal biopsy
Time Frame
4 hours
Title
Detachment and endothelial fenestration of glomeruli
Description
Measured by electron microscopy from tissue obtained by renal biopsy
Time Frame
4 hours
Title
Podocyte volume of glomeruli
Description
Measured by electron microscopy from tissue obtained by renal biopsy
Time Frame
4 hours
Title
Number and identity of RNA in kidney cells
Description
Measured from tissue obtained by renal biopsy
Time Frame
4 hours
Title
Epigenetic profiling
Description
Measured from tissue obtained by renal biopsy
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Obese youth with and without T2D (≥54 kg) and lean controls Age 12-21 years Weight <300 lbs., no implanted metal devices HbA1c < 11% and no recent diabetic ketoacidosis or hyperosmolar hyperglycemia No anemia BMI >5th percentile for lean controls Exclusion Criteria: T2D onset (diagnosis) > 18 years of age Prepubertal eGFR <60ml/min/1.73m2 or creatinine > 1.5mg/dl or history of ACR≥300mg/g ACE inhibitors, angiotensin receptor blockers (ARB), diuretics, sodium-glucose co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or aspirin, sulfonamides, procaine, thiazosulfone or probenecid. Seafood or iodine allergy Pregnancy MRI scanning contraindications (claustrophobia, implantable devices, >300 lbs) Additional exclusion criteria for participants undergoing optional kidney biopsy: Evidence of bleeding disorder or complications from bleeding Use of aspirin, NSAIDS or other blood thinner that cannot be safely stopped for a sufficient time period before and after the biopsy so as to add no additional risk of bleeding Blood urea nitrogen (BUN) > 80 gm/dL INR > 1.4 PTT > 35 seconds Hemoglobin (Hgb) < 10 mg/dL Platelet count < 100,000 / µL Uncontrolled or difficult to control hypertension (> 150/90 mmHg at the day of biopsy) eGFR < 40 mL/min/1.73m2 Single kidney (either by history, documented by prior imaging or ultrasound performed prior to the biopsy) > 2 cm discrepancy between left and right kidney sizes based on largest longitudinal diameter determined by ultrasound performed prior to the biopsy. Kidney size: One or both kidneys < 9 cm Hydronephrosis or other important renal ultrasound findings such as significant stone disease Any evidence of a current urinary tract infection as indicated on day of biopsy Clinical evidence of non-diabetic renal disease Positive urine pregnancy test or pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Petter Bjornstad, MD
Organizational Affiliation
University of Colorado School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80238
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35507146
Citation
Vigers T, Vinovskis C, Li LP, Prasad P, Heerspink H, D'Alessandro A, Reisz JA, Piani F, Cherney DZ, van Raalte DH, Nadeau KJ, Pavkov ME, Nelson RG, Pyle L, Bjornstad P. Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes. Pediatr Nephrol. 2023 Jan;38(1):193-202. doi: 10.1007/s00467-022-05531-3. Epub 2022 May 4.
Results Reference
derived
PubMed Identifier
32737116
Citation
Vinovskis C, Li LP, Prasad P, Tommerdahl K, Pyle L, Nelson RG, Pavkov ME, van Raalte D, Rewers M, Pragnell M, Mahmud FH, Cherney DZ, Johnson RJ, Nadeau KJ, Bjornstad P. Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes. Diabetes. 2020 Dec;69(12):2700-2708. doi: 10.2337/db20-0457. Epub 2020 Jul 31.
Results Reference
derived

Learn more about this trial

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

We'll reach out to this number within 24 hrs